Sandoz Group AG
A global leader in generic and biosimilar medicines.
SDZ | SW
Overview
Corporate Details
- ISIN(s):
- CH1243598427 (+2 more)
- LEI:
- 5493000JWK6XWFEUD320
- Country:
- Switzerland
- Address:
- Suurstoffi 14, 6343 Rotkreuz
- Website:
- https://www.sandoz.com/
- Sector:
- Manufacturing
Description
Sandoz Group AG is a global leader in generic and biosimilar medicines. The company's core activities involve the development, manufacturing, and distribution of off-patent pharmaceuticals to increase patient access to healthcare. Its business operates through two primary segments: Generics, which covers a wide range of small-molecule drugs, and Biosimilars, which are approved versions of original biologic medicines. Sandoz provides treatments for various diseases, including cancer and diabetes, and its product portfolio also includes key medicines such as antibiotics. The company's stated purpose is to pioneer access to medicines for patients worldwide.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-28 07:00 |
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antith…
|
English | 19.4 KB | ||
| 2025-08-28 02:00 |
Sandoz launches rivaroxaban in Germany, expanding access to high-quality antith…
|
English | 17.3 KB | ||
| 2025-08-12 02:00 |
Sandoz launches renewable energy partnership to cover nearly 90% of electricity…
|
English | 5.5 KB | ||
| 2025-08-07 02:00 |
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the se…
|
English | 67.1 KB | ||
| 2025-07-01 02:00 |
Sandoz further asserts leadership in biosimilars, breaking ground on new Sloven…
|
English | 7.7 KB | ||
| 2025-06-02 02:00 |
Sandoz launches first and only interchangeable denosumab biosimilars in US, pro…
|
English | 19.9 KB | ||
| 2025-05-21 02:00 |
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe …
|
English | 10.8 KB | ||
| 2025-03-05 01:00 |
Sandoz reports strong FY 2024 results and Q4 2024 sales
|
English | 83.1 KB | ||
| 2025-02-24 01:00 |
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new…
|
English | 21.0 KB | ||
| 2025-02-03 01:00 |
Francisco Ballester to retire; Peter Stenico appointed President Region Interna…
|
English | 5.4 KB | ||
| 2025-01-14 01:00 |
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd An…
|
English | 11.2 KB | ||
| 2024-12-17 01:00 |
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Ac…
|
English | 7.6 KB | ||
| 2024-11-15 01:00 |
Sandoz receives European Commission approval for Afqlir® (aflibercept), further…
|
English | 7.2 KB | ||
| 2024-10-30 01:00 |
Sandoz reports third-quarter and nine-month 2024 sales
|
English | 32.6 KB | ||
| 2024-08-12 02:00 |
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthe…
|
English | 9.9 KB |
Automate Your Workflow. Get a real-time feed of all Sandoz Group AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sandoz Group AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sandoz Group AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-02 | N/A | Non-Executive member | Buy | None | 251,343.62 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 270,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 260,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 230,000.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 202,500.00 CHF |
| 2025-04-15 | N/A | Non-Executive member | Buy | None | 187,500.00 CHF |
| 2024-08-21 | N/A | Non-Executive member | Buy | None | 429,855.85 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 130,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 115,000.00 CHF |
| 2024-04-30 | N/A | Non-Executive member | Buy | None | 62,500.00 CHF |
Peer Companies
